ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v24.i2.20
18 pages

Role of the IL-12/IL-23 System in the Regulation of T-Cell Responses in Central Nervous System Inflammatory Demyelination

Bruno Gran
Department of Neurology, Thomas Jefferson University, 300 Jefferson Hospital for Neuroscience, 900 Walnut Street, Philadelphia, PA 19107
Guang-Xian Zhang
Department of Neurology, Thomas Jefferson University, 300 Jefferson Hospital for Neuroscience, 900 Walnut Street, Philadelphia, PA 19107
Abdolmohamad Rostami
Department of Neurology, Thomas Jefferson University, 300 Jefferson Hospital for Neuroscience, 900 Walnut Street, Philadelphia, PA 19107

要約

Interleukin-12 (IL-12) has long been considered essential in T-cell-mediated autoimmune diseases, including multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). This is based on the strong capacity of IL-12 to induce T-cell activation and Th1 differentiation. However, recent data have shown that the perceived central role of IL-12 in CNS inflammatory demyelination is actually due to IL-23, a closely related cytokine sharing the p40 subunit and the β1 receptor chain with IL-12. There appear to be three different aspects of IL-12 involvement in EAE: (1) disease-promoting effects of exogenous IL-12, particularly in relapsing—remitting EAE and adoptive transfer EAE; (2) lack of IL-12 requirement in EAE pathogenesis, as indicated by studies in knockout mice; and (3) immunoregulatory effects of IL-12. Together, these observations make IL-12 a less attractive target for therapeutic intervention in MS. IL-23 neutralization may be a better candidate for therapeutic intervention, and it remains to be established whether blocking IL-23 with antibodies in adult mice will have the same effects as knocking out the IL-23p19 gene. Current clinical trials of neutralizing anti— IL-12 antibodies in other immune-mediated diseases target the p40 subunit, thereby neutralizing both IL-12 and IL-23. Thus, new experimental data are expected to have important implications for therapy of human diseases.


Articles with similar content:

Emerging Roles of CCCH-Type Zinc Finger Proteins in Destabilizing mRNA Encoding Inflammatory Factors and Regulating Immune Responses
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 1
Shaofei Huang, Chuanbin Yang, Yong Gu, Xuanbin Wang
Targeting the Antigen-Binding Site of HLA-Restricting Alleles in Treatment of Autoimmune Disease
Critical Reviews™ in Immunology, Vol.27, 2007, issue 3
Philip Deitiker, M. Zouhair Atassi, Minako Oshima
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases
Critical Reviews™ in Immunology, Vol.35, 2015, issue 6
Yudong Liu, Etty N. Benveniste, Hongwei Qin, Sara A. Gibson
On the Initial Trigger of Myasthenia Gravis and Suppression of the Disease by Antibodies Against the MHC Peptide Region Involved in the Presentation of a Pathogenic T-Cell Epitope
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Philip Deitiker, Minako Oshima, M. Zouhair Atassi
CD40 Signaling to the Rescue: A CD8 Exhaustion Perspective in Chronic Infectious Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 4
Dustin A. Cobb, Imtiaz A. Khan, Rajarshi Bhadra